|
Marksans Pharma has received final approval from the US Food
and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, over the counter ("OTC) bioequivalent of Advil Dual Action Tablets 250
mg/125 mg.
The Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC)are bioequivalent to the reference listed drug (RLD),Advil Dual Action of GlaxoSmithKline Consumer Healthcare Holdings (US) LLC.Advil Dual Action was first available as an over-the-counter drug in 2020.
The pivotal approval, Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg provides relief for multiple pain-related symptoms by combining two powerful ingredients indicated for OTC pain relief, ibuprofen and
acetaminophen. Ibuprofen works through the body targeting pain at the source while Acetaminophen block spain signal to the brain. The innovation takes these two powerful pain fighting ingredients and combines them into one tablet to offer fast, strong pain relief. The company plans to launch the product immediately.
|